Boehringer to acquire Actimis in $515 million deal

INGELHEIM, Germany and SAN DIEGO Boehringer Ingelheim announced Tuesday that it will acquire Actimis Pharmaceuticals in a deal worth $515 million.

The acquisition will be a structured buyout, dependent on milestones with Actimis’ asthma drug AP768, currently in Phase I testing. Should testing progress to Phase III, Boehringer will acquire all of Actimis’ shares. The deal will be complete once the development program is finished.

Founded in 1885, the Boehringer is one of the world’s 20 leading pharmaceutical companies. The family-owned company has headquarters in Ingelheim, Germany, and operates in 47 countries.

Actimis specializes in research and development of drugs to treat respiratory, inflammatory and autoimmune diseases. Headquartered in San Diego, it was spun off from Bayer Healthcare in 2004.